Ms. Lawley has extensive experience drafting and prosecuting patent applications in the U.S. and many foreign countries. Her practice focuses on biological and chemical technologies. She has experience counseling clients regarding portfolio management and rendering opinions regarding patent validity, infringement, patentability, freedom-to-operate, and inventorship.
Experience
Technologies with which Ms. Lawley has been involved include vaccines, microarray technologies, expression vectors, proteins, chemical and biological assays, antibodies, stem cells, immunotherapies, pharmaceutical compositions and formulations, antisense therapy, chimeric antigen receptors, engineered cells, gene therapies, molecular biology techniques, medical diagnostics, personalized medicine, nucleic acid sequences, blood filters, fire retardants, fluid separation technologies, and nutritional supplements. Ms. Lawley also has experience handling appeals to The Patent Trial and Appeal Board (PTAB) and an inter partes reexamination proceeding.
Professional Affiliations
- Intellectual Property Owners Association (IPO)
Languages
- German
Practices
Technologies
Insights
- Stephanie Lawley Discusses USPTO’s Revisions to the MPEP
November 22, 2024 - Leydig Sponsors IPO Annual Meeting on September 22-24 in Chicago
September 25, 2024 - Leydig Sponsors IPO Annual Meeting on September 22-24 in Chicago
September 17, 2024 - Leydig Announces 2024 Board of Directors and Officers
March 14, 2024 - Stephanie Lawley Discusses New USPTO Examination Guidelines for Evaluating Patent Enablement in view of Amgen Decision
January 24, 2024 - Stephanie Lawley Presents “Amgen v. Sanofi and Enablement Requirements” at Biopatent Forum in Frankfurt, Germany
June 21, 2023 - US Supreme Court Rules that USPTO Director May Review Decisions by the PTAB.
June 21, 2021